- Home
- LUNG vs DXR Comparison
LUNG vs DXR Comparison
Compare LUNG & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUNG | DXR |
|---|---|---|
| Founded | 1995 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.2M | 69.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LUNG | DXR |
|---|---|---|
| Price | $1.50 | $12.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $6.81 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 339.5K | 6.9K |
| Earning Date | 02-23-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $91,664,000.00 | $66,306.00 |
| Revenue This Year | $9.21 | N/A |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | ★ N/A | $34.23 |
| Revenue Growth | ★ 15.59 | N/A |
| 52 Week Low | $1.31 | $6.55 |
| 52 Week High | $9.37 | $14.76 |
Technical Indicators
Market Signals| Indicator | LUNG | DXR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.